Renaissance Technologies’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-4,231,600
| Closed | -$25.5M | – | 4011 |
|
|
2019
Q4 | $25.5M | Buy |
4,231,600
+379,000
| +10% | +$2.19M | 0.02% | 877 |
|
|
2019
Q3 | $13.9M | Buy |
3,852,600
+845,600
| +28% | +$3.26M | 0.01% | 1182 |
|
|
2019
Q2 | $8.06M | Buy |
3,007,000
+728,000
| +32% | +$2.15M | 0.01% | 1544 |
|
|
2019
Q1 | $6.75M | Buy |
2,279,000
+1,347,200
| +145% | +$3.31M | 0.01% | 1616 |
|
|
2018
Q4 | $1.48M | Buy |
931,800
+809,100
| +659% | +$2.29M | ﹤0.01% | 2387 |
|
|
2018
Q3 | $452K | Sell |
122,700
-610,220
| -83% | -$1.82M | ﹤0.01% | 2878 |
|
|
2018
Q2 | $2.07M | Sell |
732,920
-142,979
| -16% | -$487K | ﹤0.01% | 2244 |
|
|
2018
Q1 | $3.25M | Sell |
875,899
-1,306,568
| -60% | -$4.28M | ﹤0.01% | 2073 |
|
|
2017
Q4 | $6.29M | Buy |
2,182,467
+1,228,492
| +129% | +$4.46M | 0.01% | 1663 |
|
|
2017
Q3 | $4.28M | Buy |
953,975
+312,675
| +49% | +$1.39M | 0.01% | 1864 |
|
|
2017
Q2 | $2.94M | Sell |
641,300
-178,600
| -22% | -$718K | ﹤0.01% | 2042 |
|
|
2017
Q1 | $3.45M | Sell |
819,900
-125,289
| -13% | -$520K | ﹤0.01% | 1928 |
|
|
2016
Q4 | $3.9M | Buy |
945,189
+392,589
| +71% | +$2.09M | 0.01% | 1831 |
|
|
2016
Q3 | $4.48M | Buy |
+552,600
| New | +$4.7M | 0.01% | 1670 |
|
|
2016
Q1 | – | Sell |
-111,400
| Closed | -$1.2M | – | 3612 |
|
|
2015
Q4 | $1.2M | Buy |
+111,400
| New | +$1.01M | ﹤0.01% | 2376 |
|
|
2014
Q4 | – | Sell |
-897,300
| Closed | -$8.96M | – | 3203 |
|
|
2014
Q3 | $8.96M | Buy |
+897,300
| New | +$8.33M | 0.02% | 829 |
|
Renaissance Technologies's ACHN Position: Q1 2020 in Review
Renaissance Technologies sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 4,231,600 shares — an estimated $25.5M sold.
Renaissance Technologies first reported a position in ACHN in Q3 2014 and held it in 16 quarters. The position peaked at $25.5M in Q4 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Renaissance Technologies reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Renaissance Technologies sold 4,231,600 Achillion Pharmaceuticals shares in Q1 2020, an estimated $25.5M.
- Renaissance Technologies first reported a position in Achillion Pharmaceuticals in Q3 2014 and held it in 16 quarters.
- Renaissance Technologies's Achillion Pharmaceuticals position peaked at $25.5M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Renaissance Technologies's 13F filing for Q1 2020, filed 14 May 2020.